Has Christina Gray received payments from drug or device companies?

Yes. Drug and device makers reported $13,420 in general payments to Christina Gray across 744 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christina Gray did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christina Gray come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christina Gray

Adult Health · Clyde, NYNPI 1659392173

Payments from drug & device makers

$13,420in general payments, 2019–2025

Across 744 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
Pfizer$2K
Novo Nordisk$1K
AbbVie$1K
GSK$1K
Lilly USA, LLC$1K
plus $5K from 31 others

What the payments were for

Food & beverage$13,420100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	91	$1,872
Pfizer	100	$1,575
Novo Nordisk	68	$1,270
AbbVie	54	$1,184
GSK	72	$1,165
Lilly USA, LLC	76	$1,144
Edwards Lifesciences	49	$751
Bayer	36	$623
Boehringer Ingelheim	29	$575
Amgen	29	$565
Boston Scientific	11	$321
Exact Sciences	16	$293
Phathom Pharmaceuticals, Inc.	15	$270
Biosense Webster, Inc.	7	$269
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	13	$229
Takeda Pharmaceuticals U.S.A., Inc.	18	$220
Amarin Pharma, Inc.	10	$179
Johnson & Johnson	10	$170
Merck	8	$134
Astellas Pharma US Inc	4	$86
Paratek Pharmaceuticals, Inc.	4	$65
Biohaven Pharmaceutical Holding Company Ltd.	3	$64
Teva Pharmaceuticals USA, Inc.	2	$44
Aimmune Therapeutics, Inc.	2	$41
W. L. Gore & Associates, Inc.	2	$39
Xeris Pharmaceuticals, Inc.	2	$32
Collegium Pharmaceutical, Inc.	2	$29
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$29
Organon	1	$24
Mannkind Corporation	1	$24
Novartis	1	$24
Esperion Therapeutics, Inc.	1	$23
Inspire Medical Systems, Inc.	1	$20
Idorsia Pharmaceuticals US Inc	1	$19
Indivior Inc.	1	$17
Almatica Pharma LLC	1	$15
Otsuka America Pharmaceutical, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,420 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	253	$159,793
JardianceEmpagliflozin	154	$153,873
TrulicityDulaglutide	90	$100,485
OzempicSemaglutide	55	$76,083
EliquisApixaban	70	$67,253
FarxigaDapagliflozin Propanediol	45	$38,844
Breztri AerosphereBudesonide/Glycopyr/Formoterol	61	$36,460
XareltoRivaroxaban	36	$33,408
KerendiaFinerenone	17	$23,004
Synjardy XrEmpagliflozin/Metformin Hcl	25	$20,222
JanuviaSitagliptin Phosphate	17	$17,106
MounjaroTirzepatide	15	$16,075
Combivent RespimatIpratropium/Albuterol Sulfate	15	$14,767
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	19	$8,301
Breo ElliptaFluticasone/Vilanterol	21	$8,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat, Synjardy	$575	$192,342206 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta	$1,165	$184,058317 claims
Lilly USA, LLCTrulicity, Mounjaro	$1,144	$116,560105 claims
Novo NordiskOzempic	$1,270	$76,08355 claims
AstraZenecaFarxiga, Breztri Aerosphere	$1,872	$75,305106 claims
PfizerEliquis	$1,575	$67,25370 claims
Johnson & JohnsonXarelto	$170	$33,40836 claims
BayerKerendia	$623	$23,00417 claims
MerckJanuvia	$134	$17,10617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Clyde

Marguerite CallahanNew York$1.4M
Donna CatameroNew York$279K
Kristen DurkinPort Jefferson Station$255K
Katelyn McCormackAmherst$201K
Mary CiechoskiBuffalo$200K
Patricia LorussoLancaster$161K
Jennifer FioriniGlens Falls$151K
Tia AlbroRochester$142K
Maria Gigante-BaggettEast Syracuse$92K
Jane PattersonRochester$66K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →